Andrada Turcas

Andrada Turcas

Auto-generated profile, based on publicly available information

Andrada Turcas

Institute of Advanced Studies in Science and Technology, Babeș-Bolyai University, Cluj-Napoca, Romania; Radiotherapy Department, Oncology Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2023 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
ATAndrada Turcas
Andrada Turcas
DLDaniel Leucuta
Daniel Leucuta
CBCristina Balan
Cristina Balan
ECEnrico Clementel
Enrico Clementel
CGCristina Gheara
Cristina Gheara
PAPatriciu Achimas-Cadariu
Patriciu Achimas-Cadariu
Normal tissue sparing in radiotherapy relies on proper delineation. While manual contouring is time consuming and subject to inter-observer variability, auto-contouring could optimize workflows and harmonize practice. We assessed the accuracy of a commercial, deep-learning, MRI-based tool for brain organs-at-risk delineation. Thirty adult brain tumor patients were retrospectively manually recontoured. Two additional structure sets were obtained: AI (artificial intelligence) and AIedit (manually corrected auto-contours). For 15 selected cases, identical plans were optimized for each structure set. We used Dice Similarity Coefficient (DSC) and mean surface-distance (MSD) for geometric comparison and gamma analysis and dose-volume-histogram comparison for dose metrics evaluation. Wilcoxon signed-ranks test was used for paired data, Spearman coefficient(ρ) for correlations and Bland-Altman plots to assess level of agreement. Auto-contouring was significantly faster than manual (1.1/20 min, p < 0.01). Median DSC and MSD were 0.7/0.9 mm for AI and 0.8/0.5 mm for AIedit. DSC was significantly correlated with structure size (ρ = 0.76, p < 0.01), with higher DSC for large structures. Median gamma pass rate was 74% (71-81%) for Plan_AI and 82% (75-86%) for Plan_AIedit, with no correlation with DSC or MSD. Differences between Dmean_AI and Dmean_Ref were ≤ 0.2 Gy (p < 0.05). The dose difference was moderately correlated with DSC. Bland Altman plot showed minimal discrepancy (0.1/0) between AI and reference Dmean/Dmax. The AI-model showed good accuracy for large structures, but developments are required for smaller ones. Auto-segmentation was significantly faster, with minor differences in dose distribution caused by geometric variations.

11 November 2022 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
ATAndrada Turcas
Andrada Turcas
SKSarah M. Kelly
Sarah M. Kelly
ECEnrico Clementel
Enrico Clementel
DCDana Cernea
Dana Cernea
• Tomotherapy is safe and effective for cranio-spinal irradiation, both in paediatric patients and in adults, with similar disease-specific outcomes and toxicities as other techniques such as 3DCRT or IMRT/VMAT. • Tomotherapy offers several technical advantages when compared to other radiotherapy techniques such as higher target conformity and better dose homogeneity. • Helical Tomotherapy provides good organ-at-risk sparing for several structures, especially the vertebrae, parotids, and optic system. • Reported treatment time/ beam-on-time is longer with helical Tomotherapy compared to other techniques.

17 July 2023 in Radiotherapy and Oncology
Verified
Journal Article
Open access
ATAndrada Turcas
Andrada Turcas
SKSarah M Kelly
Sarah M Kelly
VBValérie Bernier-Chastagner
Valérie Bernier-Chastagner
SBStephanie Bolle
Stephanie Bolle
ACAlison Cameron
Alison Cameron
HMHenry C. Mandeville
Henry C. Mandeville
Irradiation of the vertebrae in prepubertal patients, if non-homogenous, can result in future growth deformities including kyphoscoliosis. Vertebral delineation and dosimetry were assessed for 101 paediatric cases reviewed within QUARTET-affiliated trials. Despite the availability of published consensus guidelines, a high variability in vertebral delineation was observed, with impact on dosimetry.

22 July 2024 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Open access
PDF file
ATAndrada Turcas
Andrada Turcas
BHBianca Homorozeanu
Bianca Homorozeanu
CGCristina Gheara
Cristina Gheara
CBCristina Balan
Cristina Balan
RCRodica Cosnarovici
Rodica Cosnarovici
PAPatriciu Achimas-Cadariu
Patriciu Achimas-Cadariu
Background: Craniospinal irradiation (CSI) is a complex radiotherapy (RT) technique required for treating specific brain tumors and some hematologic malignancies. With large volumes of hematogenous bone marrow (BM) being irradiated, CSI could cause acute hematologic toxicity, leading to treatment interruptions or severe complications. We report on the dynamics and dose/volume predictors of hematologic toxicity during CSI. Material and methods: Pediatric patients (≤ 18years) undergoing CSI in a tertiary cancer center were included. Medical records were retrospectively reviewed for clinical data and blood parameters were collected at baseline and weekly, until four weeks after the end of RT. The BM substructures were contoured, and dose-volume parameters were extracted. We used Wilcoxon rank-sum test to compare quantitative data, Chi square test for qualitative data and receiver operating characteristics (ROC) curves for dose/volume thresholds. Results: Fifty-one patients were included. Severe toxicities (grade 3–4) were recorded as follows: 2% anemia, 8% thrombocytopenia, 25% leukopenia, 24% neutropenia. Ninety-eight percent of patients had lymphopenia (grade 1–4) at some point. Twenty-nine percent required granulocyte-colony stimulating factor, 50% had an infection and 8% required a blood transfusion. Dmean > 3.6 Gy and V15 Gy > 10.6% for Pelvic Bones were associated with a higher risk of developing any ≥ G3 toxicities. Dmean > 30-35Gy to the Thoracic and Lumbar spine was predictive for G3–4 anemia and thrombocytopenia, and Cervical Spine Dmean > 30 Gy was associated with ≥ G3 neutropenia. Conclusion: CSI was well tolerated, without life-threatening complications in our cohort, but hematologic toxicity was frequent, with severity increasing with higher mean doses delivered to the hematogenous BM and larger volumes of BM receiving 30–35 Gy. Keywords: craniospinal irradiation radiotherapy pediatric oncology medulloblastoma toxicity

21 June 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
NGN. Gleim
N. Gleim
ATA. Turcas
A. Turcas
GMG. Minniti
G. Minniti
AGAnca-Ligia Grosu
Anca-Ligia Grosu
TKTomas Kazda
Tomas Kazda
CSClemens Seidel
Clemens Seidel
Preservation of neurocognitive function is gaining importance for patients with brain metastases (BM). Several methods of neuroprotection in radiotherapy of BM have been developed and tested in prospective clinical trials, including stereotactic radiotherapy (SRT), hippocampal-sparing whole-brain radiotherapy (HS-WBRT) and concomitant memantine. The present analysis aimed to assess the current treatment patterns in European countries. We distributed an online survey among radiation oncologists (ROs) registered within the European Society for Radiotherapy and Oncology (ESTRO). Questions included characteristics of treatment centers and institutional standard operating procedures, focusing on the use of neuroprotective measures. The survey was completed by 234 ROs from 31 countries. WBRT is the preferred treatment modality over SRT for 4-5 BM for 18 % and for 6-10 BM for 53 % of ROs. While HS-WBRT is generally offered by most ROs (85 %), only a minority apply the technique regularly (25 %), and prescription parameters vary considerably. Concomitant memantine is prescribed by 30 % of ROs. Besides concerns about available evidence, limited staff capacity and reimbursement issues constitute frequent obstacles. Boost treatments as part of WBRT are rarely performed on a regular basis (22 %). Prognostic scores are used by a majority of ROs, while cognitive tests are not. There were significant differences between higher- and lower-income countries, and between university hospitals and other centers. There is considerable heterogeneity regarding neuroprotective radiotherapy approaches in European countries and regular application is limited. Besides clinical trial results, improved technical availability and reimbursement might be required to improve their utilization for BM treatment.

23 November 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
ATAndrada Turcas
Andrada Turcas
RBRaphael Bodensohn
Raphael Bodensohn
ECElena Clerici
Elena Clerici
IDIsacco Desideri
Isacco Desideri
FEFelix Ehret
Felix Ehret
MNMaximilian Niyazi
Maximilian Niyazi
Reirradiation is increasingly considered for patients with recurrent primary brain tumours, yet clinical practices vary significantly due to limited evidence and a lack of standardized guidelines. This survey aimed to map European practice patterns in brain tumour reirradiation. A 23-item web-based survey was developed by the ESTRO CNS Focus Group to assess institutional characteristics, clinical decision-making, and technical aspects of reirradiation. Distributed via email and social media, the survey collected responses between June-July 2025. Descriptive statistics were applied. Eighty responses from 28 European countries were analysed. High-grade gliomas were the most frequently reirradiated tumours (>80 %), followed by meningioma (56 %, low-grade glioma (49 %), and ependymoma (44 %). Conventional photon radiotherapy (RT) was the predominant technique across all tumour types, with varying use of hypofractionation, stereotactic RT, and proton therapy. Target volume definition and margin size varied by histology, with larger margins and inclusion of edema/cavities more frequent in gliomas. MRI-CT fusion was standard for planning. Concurrent systemic treatment was used mainly in high-grade gliomas. Organ at risk dose recovery and cumulative constraints were commonly considered, but threshold values and recovery models differed. Main barriers included fear of toxicities, including radiation necrosis and limited evidence. This survey reveals high heterogeneity in brain tumour reirradiation practices across Europe, especially regarding dose, technique, and target definition. Despite shared principles, consensus is lacking for rarer tumour types. These findings underscore the need for harmonized guidelines and prospective data to optimize patient care.